JPWO2020132138A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132138A5 JPWO2020132138A5 JP2021531836A JP2021531836A JPWO2020132138A5 JP WO2020132138 A5 JPWO2020132138 A5 JP WO2020132138A5 JP 2021531836 A JP2021531836 A JP 2021531836A JP 2021531836 A JP2021531836 A JP 2021531836A JP WO2020132138 A5 JPWO2020132138 A5 JP WO2020132138A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- hla
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 292
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 259
- 229920001184 polypeptide Polymers 0.000 claims description 258
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 97
- 230000001105 regulatory effect Effects 0.000 claims description 65
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 230000002519 immonomodulatory effect Effects 0.000 claims description 42
- 102000043129 MHC class I family Human genes 0.000 claims description 30
- 108091054437 MHC class I family Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 21
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 21
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 16
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 14
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims description 11
- 108010002350 Interleukin-2 Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 8
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 108700004922 F42A Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 102200072413 rs121917964 Human genes 0.000 claims description 3
- 102200001405 rs377584435 Human genes 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 2
- 102100034980 ICOS ligand Human genes 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102220497892 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11_H16A_mutation Human genes 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 102100038358 Prostate-specific antigen Human genes 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 28
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 28
- 230000000735 allogeneic effect Effects 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 208000026448 Wilms tumor 1 Diseases 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024070994A JP2024105344A (ja) | 2018-12-19 | 2024-04-25 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782205P | 2018-12-19 | 2018-12-19 | |
| US62/782,205 | 2018-12-19 | ||
| US201962814707P | 2019-03-06 | 2019-03-06 | |
| US62/814,707 | 2019-03-06 | ||
| PCT/US2019/067280 WO2020132138A1 (en) | 2018-12-19 | 2019-12-18 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024070994A Division JP2024105344A (ja) | 2018-12-19 | 2024-04-25 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515331A JP2022515331A (ja) | 2022-02-18 |
| JPWO2020132138A5 true JPWO2020132138A5 (https=) | 2022-12-26 |
| JP2022515331A5 JP2022515331A5 (https=) | 2022-12-26 |
| JP7481342B2 JP7481342B2 (ja) | 2024-05-10 |
Family
ID=71100346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531836A Active JP7481342B2 (ja) | 2018-12-19 | 2019-12-18 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
| JP2024070994A Pending JP2024105344A (ja) | 2018-12-19 | 2024-04-25 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024070994A Pending JP2024105344A (ja) | 2018-12-19 | 2024-04-25 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220389079A1 (https=) |
| EP (1) | EP3897746A4 (https=) |
| JP (2) | JP7481342B2 (https=) |
| KR (1) | KR20210104700A (https=) |
| CN (1) | CN113286621A (https=) |
| AU (1) | AU2019401183A1 (https=) |
| BR (1) | BR112021011838A2 (https=) |
| CA (1) | CA3113096A1 (https=) |
| IL (1) | IL282250A (https=) |
| MX (1) | MX2021007479A (https=) |
| TW (1) | TWI856048B (https=) |
| WO (1) | WO2020132138A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| AU2019401183A1 (en) * | 2018-12-19 | 2021-08-12 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2022056015A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof |
| EP4211149A4 (en) * | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| WO2024072958A1 (en) * | 2022-09-30 | 2024-04-04 | The Children's Hospital Of Philadelphia | Systems, formulations and methods for generating universal peptide/mhc complexes with engineered disulfide connecting the heavy and light chains |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3157552T3 (pl) * | 2014-06-18 | 2020-05-18 | Albert Einstein College Of Medicine | Polipeptydy syntac i ich zastosowania |
| MY193723A (en) * | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| EP3322715B1 (en) * | 2015-07-14 | 2023-10-18 | BioNTech SE | Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof |
| CA3019005A1 (en) * | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| AU2019401183A1 (en) * | 2018-12-19 | 2021-08-12 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| CN118852456A (zh) * | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| WO2021081239A1 (en) * | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | T-cell modulatory chimeric molecules and methods of use thereof |
-
2019
- 2019-12-18 AU AU2019401183A patent/AU2019401183A1/en active Pending
- 2019-12-18 CA CA3113096A patent/CA3113096A1/en active Pending
- 2019-12-18 JP JP2021531836A patent/JP7481342B2/ja active Active
- 2019-12-18 BR BR112021011838-1A patent/BR112021011838A2/pt unknown
- 2019-12-18 KR KR1020217017809A patent/KR20210104700A/ko not_active Ceased
- 2019-12-18 EP EP19899240.6A patent/EP3897746A4/en active Pending
- 2019-12-18 WO PCT/US2019/067280 patent/WO2020132138A1/en not_active Ceased
- 2019-12-18 MX MX2021007479A patent/MX2021007479A/es unknown
- 2019-12-18 TW TW108146527A patent/TWI856048B/zh active
- 2019-12-18 CN CN201980080704.5A patent/CN113286621A/zh active Pending
-
2021
- 2021-04-12 IL IL282250A patent/IL282250A/en unknown
- 2021-05-21 US US17/327,171 patent/US20220389079A1/en not_active Abandoned
-
2024
- 2024-04-25 JP JP2024070994A patent/JP2024105344A/ja active Pending
- 2024-09-20 US US18/891,753 patent/US20250092113A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533273A5 (https=) | ||
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| KR102488477B1 (ko) | 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼 | |
| JP7481342B2 (ja) | 多量体ｔ細胞調節ポリペプチド及びその使用方法 | |
| JP2021500855A5 (https=) | ||
| KR20220066075A (ko) | T-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| JP2021500855A (ja) | 抗原提示ポリペプチドおよびその使用方法 | |
| JPWO2020243315A5 (https=) | ||
| JP7682927B2 (ja) | 特異的結合性分子 | |
| Fremont et al. | Biophysical studies of T-cell receptors and their ligands | |
| JP2017519491A5 (https=) | ||
| KR20210104673A (ko) | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| JP2022522405A (ja) | Ｔ細胞調節多量体ポリペプチド及びその使用方法 | |
| Clement et al. | Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide–MHCI tetramer staining | |
| JPWO2020132138A5 (https=) | ||
| JPWO2021055594A5 (https=) | ||
| WO2020132135A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| Lyu et al. | A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors | |
| GB2619410A (en) | Methods and compositions for cellular therapy | |
| JPWO2020257191A5 (https=) | ||
| JPWO2020132297A5 (https=) | ||
| JPWO2021081239A5 (https=) | ||
| Moro et al. | Generation of functional HLA-DR* 1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides | |
| Wagner et al. | Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1 | |
| O'Callaghan | Natural killer cell surveillance of intracellular antigen processing pathways mediated by recognition of HLA-E and Qa-1b by CD94/NKG2 receptors |